Navigenics #5 - “Corporate or pragmatic genomics?”
In this fifth article in the series of articles originating from G&H’s exclusive interview with Navigenics’ Medical Director, Dr Michael Nierenberg, we explore the contentious issue of whole genomic testing.
Navigenics uses Affymetrix’s gene chip which is able to test around 1 million genetic markers. However Navigenics has initially focused on 18 specific, treatable diseases which form the foundation of its designated SNP panel. This panel will expand over time.
I asked the question of what happened to a member’s DNA – whether it was disposed of or stored. Dr Nierenberg explained that a member’s DNA was stored in anticipation of future advances in understanding how genes and the environment interact in disease development.
“As part of a member’s subscription, we will automatically advise them of these advances if relevant to their particular disease risk as and when they become available”.
The phrases “corporate genomics” and “the Microsoft of the genome” have been coined to describe the genomic business models of companies such as Navigenics, 23andMe and deCODE Genetics where getting access to your genome would require handing it over to a company that assumes it knows better that you do which parts of your genome you are entitled to see, and then charge you again and again for updated versions of the same product.
However, the counter argument is that from modern medicine’s inception, we have effectively handed over our health to a specialist body – physicians, who themselves have grown into corporate organisations – hospitals, who, in turn are empowered to make clinical and financial judgements on our health and well-being. Is there really a tangible difference?
Dr Nierenberg defends Navigenics business model by citing the very arguments that are causing deep rifts within the genetics communities, namely, Navigenics only provides members with test results for diseases where firstly there is sufficient research on the SNPs in terms of robustness of testing, clinical utility and outcomes, and secondly, but importantly, the diseases they focus on are those where something can be done to reduce the risk of developing that disease - such as exercise, nutrition and regular screening.
Imagine the confusion and furore if Navigenics were to provide its members with their full 1 million marker analysis! Navigenics’ (and others) sensible, if somewhat patriarchal approach of ‘drip feeding’ results to members as and when the research is robust enough to bring the SNP into the public domain, is one that should be applauded not derided. Yes, they and others have the potential to make substantial profits if consumers chose the service. But the corporate world is also littered with the carcasses of companies that didn’t get it right.
To learn more about the company and its thoughts on key issues surrounding the genomics industry, look out for the following articles which will be posted throughout this week.
Navigenics #3 - SNP testing – can it be used for disease risk assessment?
Navigenics #4 - Low penetrance v high penetrance genes
Navigenics #6 - Privacy, insurance, GINA and ethics
Related Stories
POSTED IN: General Genetics and Health, Genetic Ethics, Genetic Testing, Genetic legislation, Genetics Interviews, Navigenics, Personal Genomics Services, Personalized Medicine
.gif)
1 opinion for Navigenics #5 - “Corporate or pragmatic genomics?”
Steven Murphy MD
Apr 11, 2008 at 2:20 pm
Nice series of articles. I thank you for them. I didn’t know you founded Opaldia. I should have come to you when we started Helix Health.
-Steve
http://www.helixhealth.org
Have an opinion? Leave a comment: